<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989833</url>
  </required_header>
  <id_info>
    <org_study_id>D5890L00032</org_study_id>
    <nct_id>NCT00989833</nct_id>
  </id_info>
  <brief_title>Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients</brief_title>
  <acronym>MIA</acronym>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol &quot;As-needed&quot;, or Terbutaline &quot;As-needed&quot; or Regular Use of Budesonide + Terbutaline &quot;As-needed&quot;, in Patients With Mild Intermittent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The primary objective of this study is:

             -  To evaluate the magnitude of the protective effect of the combination of budesonide
                and formoterol on an as-needed basis compared to the use of terbutaline as-needed
                on exercise induced bronchoconstriction in adults and adolescents with mild
                intermittent asthma

        2. The secondary objectives of this study are:

             -  To evaluate the magnitude of the protective effect of the combination of budesonide
                and formoterol as-needed compared to regular once daily use of budesonide plus
                terbutaline as-needed on exercise induced bronchoconstriction in adults and
                adolescents with mild intermittent asthma

             -  To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and
                regular use of budesonide + terbutaline as-needed as terms of adverse event
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks</measure>
    <time_frame>Baseline and Visit 6</time_frame>
    <description>FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial Responsiveness to Mannitol</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Exhaled Nitric Oxide</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of as Needed Medication</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean number of as needed inhalations taken before exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)</measure>
    <time_frame>Baseline e and 6 weeks</time_frame>
    <description>Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diary Recording of Asthma Symptoms</measure>
    <time_frame>6 weeks</time_frame>
    <description>Asthma symptoms during days with exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Adverse Event During the Study</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Exercise Induced Asthma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>budesonide 400yg + terbutaline 0.4 mg as-needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo + terbutaline 0.4 mg as-needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo + budesonide/formoterol 160/4.5 yg as-needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>400 yg x 1</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Pulmicort Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbutaline</intervention_name>
    <description>0.4 mg as-needed</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Bricanyl Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol</intervention_name>
    <description>160/4.5 yg as-needed</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of exercise induced asthma

          -  Maximum 4 asthmatic episodes per week requiring use of reliever medication

        Exclusion Criteria:

          -  No previous treatment with inhaled oral corticosteroids during the last month before
             randomisation

          -  Suspected poor capability to follow instructions, ie to exercise 3-4 times a week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjell Larsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca MC Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georgios Stratelis</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca MC Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skene</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <results_first_submitted>August 22, 2011</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise induced asthma</keyword>
  <keyword>Mild intermittent asthma</keyword>
  <keyword>Exercise induced bronchoconstriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Asthma, Exercise-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>On Visit 1, a total of 189 patients, aged 12-67, were enrolled at 10 study sites in 2 countries: Sweden and Norway. Of 189 enrolled patients, 66 patients were randomized and allocated to study treatment on Visit 3 (7 patients in Norway and 59 patients in Sweden).</recruitment_details>
      <pre_assignment_details>A standardized exercise test (ECT) with duration of 6 minutes, at approximately 90% of maximal aerobic capacity (as defined on Visit 1) was performed on a treadmill while breathing dry air on Visit 2. Patients with exercised induced bronchoconstriction (defined as fall in FEV1 ≥ 10% ) could be randomized on Visit 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Budesonide/Terbutaline</title>
          <description>Budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="P2">
          <title>Terbutaline</title>
          <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="P3">
          <title>Budesonide/Formoterol</title>
          <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrectly randomized</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide/Terbutaline</title>
          <description>Budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="B2">
          <title>Terbutaline</title>
          <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="B3">
          <title>Budesonide/Formoterol</title>
          <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks</title>
        <description>FEV1</description>
        <time_frame>Baseline and Visit 6</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks</title>
          <description>FEV1</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.85" spread="6.50"/>
                    <measurement group_id="O2" value="0.61" spread="10.92"/>
                    <measurement group_id="O3" value="-5.24" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks</title>
        <description>FEV1</description>
        <time_frame>Baseline and 3 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks</title>
          <description>FEV1</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" spread="5.56"/>
                    <measurement group_id="O2" value="-1.19" spread="8.03"/>
                    <measurement group_id="O3" value="-3.81" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchial Responsiveness to Mannitol</title>
        <description>Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15)</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchial Responsiveness to Mannitol</title>
          <description>Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15)</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.26" spread="141.98"/>
                    <measurement group_id="O2" value="-6.15" spread="95.10"/>
                    <measurement group_id="O3" value="151.87" spread="141.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Exhaled Nitric Oxide</title>
        <time_frame>6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Exhaled Nitric Oxide</title>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>ppb</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="20.1"/>
                    <measurement group_id="O2" value="35.5" spread="36.6"/>
                    <measurement group_id="O3" value="24.4" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of as Needed Medication</title>
        <description>Mean number of as needed inhalations taken before exercise</description>
        <time_frame>6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Use of as Needed Medication</title>
          <description>Mean number of as needed inhalations taken before exercise</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>number of inhalations per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.5"/>
                    <measurement group_id="O3" value="0.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)</title>
        <description>Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk.</description>
        <time_frame>Baseline e and 6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)</title>
          <description>Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk.</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.8"/>
                    <measurement group_id="O3" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diary Recording of Asthma Symptoms</title>
        <description>Asthma symptoms during days with exercise</description>
        <time_frame>6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Diary Recording of Asthma Symptoms</title>
          <description>Asthma symptoms during days with exercise</description>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>Percent of exercise days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="30.5"/>
                    <measurement group_id="O2" value="50.9" spread="36.6"/>
                    <measurement group_id="O3" value="49.8" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Adverse Event During the Study</title>
        <time_frame>6 weeks</time_frame>
        <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide/Terbutaline</title>
            <description>Budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
          </group>
          <group group_id="O3">
            <title>Budesonide/Formoterol</title>
            <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event During the Study</title>
          <population>The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Budesonide/Terbutaline</title>
          <description>Budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="E2">
          <title>Terbutaline</title>
          <description>Placebo budesonide once daily and terbutaline before exercise and as needed</description>
        </group>
        <group group_id="E3">
          <title>Budesonide/Formoterol</title>
          <description>Placebo budesonide once daily and budesonide/formoterol before exercise and as needed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Slight Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Common cold</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

